Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Azacyclonol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 3/20 | 0.93 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.93 |
| ▸ | MEN1 | O00255 | 1/20 | 0.93 |
| ▸ | LMNA | P02545 | 1/20 | 0.93 |
| ▸ | SCN1A | P35498 | 1/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.93 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.93 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.93 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azacyclonol SCHEMBL241817 | 0.96 | HRH1 (1.00) | HRH1CYP2D6MEN1LMNASCN1A | |
| Azacyclonol SCHEMBL1890138 | 0.94 | HRH1 (0.96) | HRH1CYP2D6MEN1LMNASCN1A | |
| Azacyclonol SCHEMBL6135637 | 0.94 | HRH1 (0.96) | HRH1CYP2D6MEN1LMNASCN1A | |
| SCHEMBL11395372 | 0.88 | CYP2D6 (0.83) | HRH1CYP2D6MEN1LMNASCN1A | |
| Azacyclonol SCHEMBL27517195 | 0.88 | HRH1 (0.83) | HRH1CYP2D6MEN1LMNASCN1A | |
| SCHEMBL11831606 | 0.86 | HRH1 (0.81) | HRH1CYP2D6MEN1LMNASCN1A | |
| SCHEMBL7328353 | 0.86 | CYP2D6 (0.81) | HRH1CYP2D6MEN1LMNASCN1A | |
| SCHEMBL11835095 | 0.86 | CYP2D6 (0.81) | HRH1CYP2D6MEN1LMNASCN1A | |
| SCHEMBL11832155 | 0.86 | CYP2D6 (0.81) | HRH1CYP2D6MEN1LMNASCN1A | |
| SCHEMBL13923571 | 0.86 | HRH1 (0.81) | HRH1CYP2D6MEN1LMNASCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071438-B | Process for preparing fexofenadine and intermediates used therein | 赛诺菲-安万特德国有限公司 | 2023-02-21 | — | — | CN | disclosed |
| US-10696633-B2 | Process for the preparation of fexofenadine and of intermediates used therein | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| EP-3365327-B1 | PROCESS FOR THE PREPARATION OF FEXOFENADINE AND OF INTERMEDIATES USED THEREIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2019-11-20 | — | — | EP | disclosed |
| US-20180297951-A1 | PROCESS FOR THE PREPARATION OF FEXOFENADINE AND OF INTERMEDIATES USED THEREIN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2018-10-18 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696633-B2 | Process for the preparation of fexofenadine and of intermediates used therein | CYP4F2, CYP4F3, NISCH | CHRM3 1007/4885HRH1 39/4885CYP2D6 85/4885 |
| US-20180297951-A1 | PROCESS FOR THE PREPARATION OF FEXOFENADINE AND OF INTERMEDIATES USED THEREIN | CYP4F2, CYP4F3, NISCH | CHRM3 1007/4885HRH1 39/4885CYP2D6 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.